Working my way through the abstracts released today for presentation at the ASH convention in December, I note that in addition to those substantiating the activity of carfilzomib in multiple myeloma, there is an interesting one on ONXX's monoclonal antibody, elotuzumab. (Carfilzomib is a proteasome inhibitor.) This also seems to be highly effective in MM patients, producing a 96% response rate after 4 cycles of treatment. Since I believe that this would be the first monoclonal antibody for this disease, this seems to my inexpert eye that it may be even more significant than carfilzomib, which has well-established competition in Velcade.
Okay, now that I've untangled my notes, I see that this is really a Bristol-Myers drug. The abstract which interested me relative to carfilzomib (Kyrpolis) was one which suggested that in addition to activity vs MM, it may also have broad scale usage in a whole range of auto-immune disease, since it seems to activate T-cells.